100 Recruiting Studies Using Trastuzumab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Trastuzumab
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
π University of Alabama at Birmingham β Birmingham, Alabama
Metastatic Breast Cancer
View Study & Checklist βRadiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
π Moffitt Cancer Center β Tampa, Florida
HER2-positive Breast Cancer
View Study & Checklist βNeratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer
π Moffitt Cancer Center β Tampa, Florida
GastroEsophageal Cancer
View Study & Checklist βT-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Anatomic Stage II Breast Cancer AJCC v8
View Study & Checklist βA Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
π Research Site β Tucson, Arizona
Triple Negative Breast Neoplasms
View Study & Checklist βNeoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]
π Cedars Sinai Medical Center β Los Angeles, California
HER2-positive Breast Cancer
View Study & Checklist βELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
π University of Colorado - Anschutz Medical Campus - PPDS β Aurora, Colorado
HER2 Mutant Non-small Cell Lung Cancer
View Study & Checklist βPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
π Research Site β Baltimore, Maryland
Gastric Cancer
View Study & Checklist βTucatinib+Trastuzumab+Eribulin in HER2+ MBC
π University of Colorado β Aurora, Colorado
Breast Cancer
View Study & Checklist βA Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial
π Santa Casa de Misericordia de Porto Alegre β Porto Alegre, Rio Grande do Sul
Solid Tumors
View Study & Checklist βFirst-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
π California Cancer Associates for Research and Excellence β Encinitas, California
Advanced Cancer
View Study & Checklist βTo Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
π Massachusetts General Hospital. β Boston, Massachusetts
Breast Cancer
View Study & Checklist βPersonalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 Treatment
π Natera β San Carlos, Texas
Breast Cancer, Metastatic
View Study & Checklist βCu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
π City of Hope Medical Center β Duarte, California
HER2 Positive Breast Carcinoma
View Study & Checklist βTrial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
π 10 sites incl TX, WA, VA, and NV β Dallas, Texas
Breast Neoplasms
View Study & Checklist βPilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma
π Children's Hospital Colorado β Aurora, Colorado
Posterior Fossa Ependymoma (PFEPN)
View Study & Checklist βELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
π BRCR Medical Center Inc. β Plantation, Florida
HER2-positive Breast Cancer
View Study & Checklist βPertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
π University of Alabama Comprehensive Cancer Center β Birmingham, Alabama
Breast Cancer
View Study & Checklist βTrastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
π Research Site β Springdale, Arkansas
Breast Neoplasms
View Study & Checklist βPHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
π Dana-Farber Cancer Institute β Boston, Massachusetts
HER2-positive Breast Cancer
View Study & Checklist βDS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
π UCLA Hematology Oncology β Los Angeles, California
Breast Cancer
View Study & Checklist βRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
π UCLA / Jonsson Comprehensive Cancer Center β Los Angeles, California
Anatomic Stage II Breast Cancer AJCC v8
View Study & Checklist βA Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
π Research Site β Commack, New York
Metastatic Breast Cancer
View Study & Checklist βTesting the Biological Effects of DS-8201a on Patients With Advanced Cancer
π National Cancer Institute Developmental Therapeutics Clinic β Bethesda, Maryland
Advanced Malignant Solid Neoplasm
View Study & Checklist βTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Advanced Lymphoma
View Study & Checklist βPhase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
π Research Site β Duarte, California
Non-Small Cell Lung Cancer
View Study & Checklist βStudy of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation
π Highlands Oncology Group β Fayetteville, Arkansas
Advanced HER2+Breast Cancer
View Study & Checklist βA Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
π Research Site β Duarte, California
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer
View Study & Checklist βThe AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
π University of Alabama at Birmingham β Birmingham, Alabama
Breast Cancer
View Study & Checklist βTrastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
π Ironwood Cancer & Research Centers - Chandler II β Chandler, Arizona
Breast Cancer
View Study & Checklist βPhase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
π UC Irvine Health/Chao Family Comprehensive Cancer Center β Orange, California
Breast Carcinoma
View Study & Checklist βCompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Anatomic Stage II Breast Cancer AJCC v8
View Study & Checklist βA Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
π Highlands Oncology Group - Duplicate 2 β Rogers, Arkansas
Breast Neoplasms
View Study & Checklist βRandomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
π UCSF β San Francisco, California
HER-2 Positive Breast Cancer
View Study & Checklist βExtension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
π University of Alabama - Birmingham β Birmingham, Alabama
Breast Cancer
View Study & Checklist βA Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
π Research Site β Boston, Massachusetts
Breast Cancer
View Study & Checklist βA Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
π UCSF Helen Diller Family CCC β San Francisco, California
Ovarian Cancer
View Study & Checklist βA Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
π Research Site β Fort Myers, Florida
Metastatic Breast Cancer
View Study & Checklist βDAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
π Massachusetts General Hospital β Boston, Massachusetts
Breast Cancer
View Study & Checklist βA Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
π Research Site β Santa Rosa, California
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
View Study & Checklist βA Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
π Hospital de GastroenterologΓa Dr Bonorino Udaondo β Buenos Aires,
Gastric Neoplasms
View Study & Checklist βStudy of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer
π Research Site β Scottsdale, Arizona
Advanced or Metastatic Breast Cancer
View Study & Checklist βTumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
π Western Regional Medical Center at Cancer Treatment Centers of America β Goodyear, Arizona
Solid Tumors
View Study & Checklist βTolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
π City of Hope Medical Center β Duarte, California
Breast Neoplasms
View Study & Checklist βA Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
π City of Hope National Medical Center β Duarte, California
Neoplasm Metastasis
View Study & Checklist βAdjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction
π Weill Cornell Medicine/New York-Presbyterian β New York, New York
Esophageal Adenocarcinoma
View Study & Checklist βPhase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
π M D Anderson Cancer Center β Houston, Texas
Breast Cancer
View Study & Checklist βA Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
π Mayo Clinic Hospital β Phoenix, Arizona
HER2 Positive Breast Cancer
View Study & Checklist βA Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
π Banner MD Anderson Cancer Center β Gilbert, Arizona
Breast Cancer
View Study & Checklist βA Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
π Yale University β New Haven, Connecticut
Solid Tumors
View Study & Checklist βDurvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
π Houston Methodist Cancer Center β Houston, Texas
Breast Cancer
View Study & Checklist βA Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
π The Oncology Institute of Hope & Innovation β Anaheim, California
Gastric Cancer
View Study & Checklist βTucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
π Mayo Clinic Hospital β Phoenix, Arizona
Colorectal Carcinoma
View Study & Checklist βEvaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
π The Ottawa Hospital Cancer Centre β Ottawa, Ontario
Breast Cancer
View Study & Checklist βTesting Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
π ECOG-ACRIN Cancer Research Group β Philadelphia, Pennsylvania
Malignant Solid Neoplasm
View Study & Checklist βCombination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
π City of Hope Medical Center β Duarte, California
Breast Cancer
View Study & Checklist βNecitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
π UCLA / Jonsson Comprehensive Cancer Center β Los Angeles, California
Metastatic Lung Non-Small Cell Carcinoma
View Study & Checklist βDS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
π Univ. of Cali. San Francisco Medical Center β San Francisco, California
Breast Cancer
View Study & Checklist βTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
π Research Site β Tucson, Arizona
Breast Cancer; HER2-positive; Metastatic
View Study & Checklist βTesting Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
π ECOG-ACRIN Cancer Research Group β Philadelphia, Pennsylvania
Advanced Lymphoma
View Study & Checklist βCopper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
π City of Hope Medical Center β Duarte, California
Bone Metastases
View Study & Checklist βA Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
π Alabama Oncology β Birmingham, Alabama
Breast Cancer
View Study & Checklist βMARGetuximab Or Trastuzumab (MARGOT)
π Georgetown University Medical Center β Washington D.C., District of Columbia
Breast Cancer
View Study & Checklist βAnastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast
π Mount Sinai Beth Israel Comprehensive Cancer Center West β New York, New York
Breast Neoplasms
View Study & Checklist βTesting the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
π UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care β Irvine, California
Advanced Breast Carcinoma
View Study & Checklist βA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
π Research Site β Anchorage, Alaska
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
View Study & Checklist βA Study to Investigate Safety and Tolerability of TransCon IL-2 Ξ²/Ξ³ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
π Ascendis Pharma Investigational Site β Los Angeles, California
Advanced Solid Tumor
View Study & Checklist βA Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
π Miami Cancer Institute at Baptist Health β Miami, Florida
Her 2 Positive Breast Cancer
View Study & Checklist βSecondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
π University of California San Francisco β San Francisco, California
Brain Metastases
View Study & Checklist βBasket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
π HonorHealth β Phoenix, Arizona
Uterine Neoplasms
View Study & Checklist βClinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
π Fox Chase Cancer Center β Philadelphia, Pennsylvania
HER2-positive Breast Cancer
View Study & Checklist βTrastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases
π Miami Cancer Institute at Baptist Health, Inc. β Miami, Florida
Breast Cancer
View Study & Checklist βTrastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer
π Washington University School of Medicine β St Louis, Missouri
Breast Cancer
View Study & Checklist βASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
π MD Anderson Cancer Center β Houston, Texas
Dynamic Tumor Resistance
View Study & Checklist βPhase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers
π UT MD Anderson β Houston, Texas
Breast Cancer
View Study & Checklist βScalp Cooling in MBC
π Brigham and Women's Hospital β Boston, Massachusetts
Metastatic Breast Cancer
View Study & Checklist βTesting the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
π University of Alabama at Birmingham Cancer Center β Birmingham, Alabama
Metastatic Salivary Gland Carcinoma
View Study & Checklist βSequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
π Moffitt Cancer Center β Tampa, Florida
Metastatic Breast Cancer
View Study & Checklist βDESTINY-PANTUMOUR04
π Research Site β Birmingham, Alabama
Adenocarcinoma (NOS)
View Study & Checklist βStudy of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
π Moffitt Cancer Center β Tampa, Florida
HER2-positive Breast Cancer
View Study & Checklist βStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
π Yale Cancer Center β New Haven, Connecticut
Gastric Cancer
View Study & Checklist βAn Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
π City of Hope Medical Center β Duarte, California
Anatomic Stage IV Breast Cancer AJCC v8
View Study & Checklist βOxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma
π University of Wisconsin Carbone Cancer Center β Madison, Wisconsin
Esophageal Adenocarcinoma
View Study & Checklist βBRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
π University of Illinois β Chicago, Illinois
Breast Cancer
View Study & Checklist βConcurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
π Fred Hutch/University of Washington Cancer Consortium β Seattle, Washington
Anatomic Stage I Breast Cancer AJCC v8
View Study & Checklist βA Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer
π University of Michigan (Data Collection Only) β Ann Arbor, Michigan
Non-Small Cell Lung Cancer
View Study & Checklist βOptimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
π RWJBarnabas Health - Trinitas Hospital and Comprehensive Cancer Center β Elizabeth, New Jersey
HER2-positive Early-stage Breast Cancer
View Study & Checklist βA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
π Southern Cancer Center (SCC) ( Site 8000) β Daphne, Alabama
Breast Neoplasms
View Study & Checklist βStudy of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
π Alaska Oncology & Hematology, LLC β Anchorage, Alaska
Non-small Cell Lung Cancer
View Study & Checklist βTesting the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
π City of Hope Comprehensive Cancer Center β Duarte, California
Metastatic Malignant Solid Neoplasm
View Study & Checklist βA Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
π City of Hope Comprehensive Cancer Center β Duarte, California
Endometrial Cancer
View Study & Checklist βCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
π Cross Cancer Institute β Edmonton, Alberta
Lymphoma, Non-Hodgkin
View Study & Checklist βSotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
π University of California Davis Comprehensive Cancer Center β Sacramento, California
Locally Advanced Lung Non-Small Cell Carcinoma
View Study & Checklist βATEMPT 2.0: Adjuvant T-DM1 vs TH
π UCSF Helen Diller Family Comprehensive Cancer Center β San Francisco, California
Breast Cancer
View Study & Checklist βResponse Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)
π Chao Family Comprehensive Cancer Center, University β Orange, California
Gastroesophageal Adenocarcinoma
View Study & Checklist βA Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
π Massachusetts General Hospital (Data Collection Only) β Boston, Massachusetts
Esophageal Cancer
View Study & Checklist βA Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
π Palo Verde Hematology Oncology β Glendale, Arizona
Colorectal Neoplasms
View Study & Checklist βBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
π The Oncology Institute of Hope and Innovation β Cerritos, California
Metastatic Breast Cancer
View Study & Checklist βA Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
π Mayo Clinic in Arizona β Scottsdale, Arizona
Advanced Solid Tumor
View Study & Checklist βFT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
π University of Southern California β La Jolla, California
Non-Small Cell Lung Cancer
View Study & Checklist β